Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142816 | 0.93 | SYK (0.52) | SYKIDO1MEN1KMT2ALMNA | |
| SCHEMBL24801254 | 0.92 | SYK (0.49) | SYKIDO1MEN1KMT2AMAPT | |
| SCHEMBL31041112 | 0.89 | LMNA (0.59) | SYKIDO1MEN1KMT2ALMNA | |
| SCHEMBL8238491 | 0.89 | SYK (0.61) | SYKIDO1MEN1KMT2AMAPT | |
| SCHEMBL18429488 | 0.89 | SYK (0.53) | SYKIDO1MEN1KMT2ALMNA | |
| SCHEMBL15202883 | 0.86 | SYK (0.64) | SYKIDO1LMNASMN1; SMN2MAPT | |
| SCHEMBL22241718 | 0.86 | SYK (0.53) | SYKIDO1MEN1KMT2AMAPT | |
| SCHEMBL1328864 | 0.86 | MAPT (0.51) | SYKMAPTL3MBTL1MAPK1 | |
| SCHEMBL3955009 | 0.85 | SYK (0.57) | SYKIDO1MEN1KMT2ALMNA | |
| SCHEMBL25868619 | 0.85 | SYK (0.57) | SYKIDO1LMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20110301230-A1 | GENE CARRIER | TAITO CO., LTD (JP) | 2011-12-08 | — | — | US | disclosed |
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| EP-1105525-B1 | A PROCESS FOR PREPARING PEPTIDE NUCLEIC ACID PROBE USING POLYMERIC PHOTOACID GENERATOR | SAMSUNG ELECTRONICS CO LTD (KR) | 2006-11-02 | — | — | EP | disclosed |
| US-6660479-B2 | Derivatizing surface of a solid matrix and attaching linker with acid- labile protecting group on solid matrix; coating solid matrix with polymeric photoacid generator(PAG); exposing solid matrix thus coated to light to generate acid; reacting | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2003-12-09 | — | — | US | disclosed |
| US-20020122874-A1 | Process for preparing peptide nucleic acid probe using polymeric photoacid generator | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2002-09-05 | — | — | US | disclosed |
| US-6359125-B1 | DERIVATIZING SURFACE OF SOLID MATRIX WITH AMINOALKYLOXYSILANE AND ATTACHING LINKER WITH ACID-LABILE PROTECTING GROUP TO AMINE GROUP ON MATRIX, COATING MATRIX WITH POLYMERIC PHOTOACID GENERATOR, EXPOSING TO LIGHT, ATTACHING PEPTIDE NUCLEIC ACID | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2002-03-19 | — | — | US | disclosed |
| US-5344830-A | Anitinflammatory, cardiovascular, analgesic, central nervous system | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| WO-1994013646-A1 | N,N-DIACYLPIPERAZINE TACHYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | SYK 2786/4885IDO1 1319/4885MEN1 1703/4885 |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | SYK 3727/4885IDO1 1734/4885MEN1 3100/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | SYK 2786/4885IDO1 1319/4885MEN1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.